Skip to main content

Regeneron shares fall after FDA rejects high-dose eye disease treatment

Regeneron said the rejection was "solely due to an ongoing review of inspection findings at a third-party filler."
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.